BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95. [PMID: 15987917 DOI: 10.1056/NEJMoa043470] [Cited by in Crossref: 1093] [Cited by in F6Publishing: 323] [Article Influence: 68.3] [Reference Citation Analysis]
Number Citing Articles
1 Tan G, Song H, Xu F, Cheng G. When Hepatitis B Virus Meets Interferons. Front Microbiol 2018;9:1611. [PMID: 30072974 DOI: 10.3389/fmicb.2018.01611] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
2 Saraceni C, Birk J. A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis. J Clin Transl Hepatol 2021;9:409-18. [PMID: 34221927 DOI: 10.14218/JCTH.2020.00095] [Reference Citation Analysis]
3 Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, Li S, Li W, Block TM, Chang J, Guo JT. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog. 2013;9:e1003613. [PMID: 24068929 DOI: 10.1371/journal.ppat.1003613] [Cited by in Crossref: 107] [Cited by in F6Publishing: 101] [Article Influence: 13.4] [Reference Citation Analysis]
4 Fu WK, Cao J, Mi NN, Huang CF, Gao L, Zhang JD, Yue P, Bai B, Lin YY, Meng WB. Cytokines predict virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy. World J Clin Cases 2020; 8(11): 2255-2265 [PMID: 32548156 DOI: 10.12998/wjcc.v8.i11.2255] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Leung NW, Herrmann E, Lau GK, Chan HL, So TM, Zeuzem S, Dong Y, Trylesinski A, Naoumov NV. Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Infect Dis Ther 2014;3:191-202. [PMID: 25228496 DOI: 10.1007/s40121-014-0039-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
6 Wilson EM, Tang L, Kottilil S. Eradication Strategies for Chronic Hepatitis B Infection. Clin Infect Dis 2016;62 Suppl 4:S318-25. [PMID: 27190322 DOI: 10.1093/cid/ciw044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
7 Wu GY, Chen HS. Novel approaches towards conquering hepatitis B virus infection. World J Gastroenterol 2007; 13(6): 830-836 [PMID: 17352010 DOI: 10.3748/wjg.v13.i6.830] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cai S, Cao J, Yu T, Xia M, Peng J. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine (Baltimore) 2017;96:e7021. [PMID: 28562554 DOI: 10.1097/MD.0000000000007021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
9 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
10 de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 2020;55:496-514. [PMID: 32185517 DOI: 10.1007/s00535-020-01680-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
11 Rijckborst V, Janssen HL. The Role of Interferon in Hepatitis B Therapy. Curr Hepat Rep 2010;9:231-8. [PMID: 20949114 DOI: 10.1007/s11901-010-0055-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
12 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol 2012; 18(48): 7149-7157 [PMID: 23326119 DOI: 10.3748/wjg.v18.i48.7149] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
13 Hsu CW, Chen YC, Chang ML, Lin CC, Lin SM, Chen WT, Chu YD, Yeh CT. Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients. Open Forum Infect Dis 2018;5:ofx271. [PMID: 29362723 DOI: 10.1093/ofid/ofx271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Chen XL, Li M, Zhang XL. HBV genotype B/C and response to lamivudine therapy: a systematic review. Biomed Res Int. 2013;2013:672614. [PMID: 24364035 DOI: 10.1155/2013/672614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
15 Ooi EL, Chan ST, Cho NE, Wilkins C, Woodward J, Li M, Kikkawa U, Tellinghuisen T, Gale M Jr, Saito T. Novel antiviral host factor, TNK1, regulates IFN signaling through serine phosphorylation of STAT1. Proc Natl Acad Sci U S A 2014;111:1909-14. [PMID: 24449862 DOI: 10.1073/pnas.1314268111] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
16 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Fu B, Wang D, Shen X, Guo C, Liu Y, Ye Y, Sun R, Li J, Tian Z, Wei H. Immunomodulation Induced During Interferon-α Therapy Impairs the Anti-HBV Immune Response Through CD24+CD38hi B Cells. Front Immunol 2020;11:591269. [PMID: 33424840 DOI: 10.3389/fimmu.2020.591269] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Yang J, Zhao LS. Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short report. Virol J 2009;6:97. [PMID: 19583877 DOI: 10.1186/1743-422X-6-97] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev 2019;8:207. [PMID: 31426837 DOI: 10.1186/s13643-019-1126-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
20 Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008;2:284-95. [PMID: 19669256 DOI: 10.1007/s12072-008-9049-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
21 Tsai MC, Chen YT, Chien YS, Chen TC, Hu TH. Hepatitis B virus infection and renal transplantation. World J Gastroenterol 2010; 16(31): 3878-3887 [PMID: 20712048 DOI: 10.3748/wjg.v16.i31.3878] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
22 Hui CK, Bowden S, Zhang HY, Wong A, Lewin S, Rousseau F, Mommeja-Marin H, Lee NP, Luk JM, Locarnini S, Leung N, Naoumov NV, Lau GK. Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy. J Clin Microbiol 2006;44:2983-7. [PMID: 16891522 DOI: 10.1128/JCM.02544-05] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
23 Santantonio TA, Fasano M. Chronic hepatitis B: Advances in treatment. World J Hepatol 2014; 6(5): 284-292 [PMID: 24868322 DOI: 10.4254/wjh.v6.i5.284] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
24 Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, Jacobson JM, Johnson VA, Pollard RB, Rooney JF. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology. 2006;44:1110-1116. [PMID: 17058225 DOI: 10.1002/hep.21388] [Cited by in Crossref: 133] [Cited by in F6Publishing: 105] [Article Influence: 8.9] [Reference Citation Analysis]
25 Yong YK, Saeidi A, Tan HY, Rosmawati M, Enström PF, Batran RA, Vasuki V, Chattopadhyay I, Murugesan A, Vignesh R, Kamarulzaman A, Rajarajeswaran J, Ansari AW, Vadivelu J, Ussher JE, Velu V, Larsson M, Shankar EM. Hyper-Expression of PD-1 Is Associated with the Levels of Exhausted and Dysfunctional Phenotypes of Circulating CD161++TCR iVα7.2+ Mucosal-Associated Invariant T Cells in Chronic Hepatitis B Virus Infection. Front Immunol 2018;9:472. [PMID: 29616020 DOI: 10.3389/fimmu.2018.00472] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
26 Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, Flaherty JF, Massetto B, Lin L, Dinh P, Subramanian GM, McHutchison JG, Flisiak R, Gurel S, Dusheiko GM, Heathcote EJ. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol. 2014;61:1228-1237. [PMID: 25046847 DOI: 10.1016/j.jhep.2014.07.019] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 9.1] [Reference Citation Analysis]
27 Sagnelli C, Sagnelli E. Towards the worldwide eradication of hepatitis B virus infection: A combination of prophylactic and therapeutic factors. World J Clin Infect Dis 2019; 9(2): 11-22 [DOI: 10.5495/wjcid.v9.i2.11] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 顾生旺, 吴德平, 李荣清. 恩替卡韦联合或序贯干扰素治疗慢性乙型肝炎的现状、问题与前景. 世界华人消化杂志 2016; 24(18): 2799-2810 [DOI: 10.11569/wcjd.v24.i18.2799] [Reference Citation Analysis]
29 Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med. 2015;5. [PMID: 25833942 DOI: 10.1101/cshperspect.a021501] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 15.3] [Reference Citation Analysis]
30 Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, Wei L, Chang J, Block TM, Guo JT. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol. 2010;84:9332-9340. [PMID: 20610715 DOI: 10.1128/jvi.00918-10] [Cited by in Crossref: 91] [Cited by in F6Publishing: 59] [Article Influence: 8.3] [Reference Citation Analysis]
31 Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55:2727-2734. [PMID: 20238245 DOI: 10.1007/s10620-010-1179-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
32 Jiang XW, Ye JZ, Li YT, Li LJ. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol 2018; 24(28): 3181-3191 [PMID: 30065564 DOI: 10.3748/wjg.v24.i28.3181] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
33 Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review. World J Gastroenterol 2014; 20(40): 14598-14614 [PMID: 25356024 DOI: 10.3748/wjg.v20.i40.14598] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
34 Liu YH, Wu T, Sun N, Wang GL, Yuan JZ, Dai YR, Zhou XH. Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study. J Huazhong Univ Sci Technolog Med Sci 2014;34:542-7. [PMID: 25135724 DOI: 10.1007/s11596-014-1312-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
35 Zhu MY, Chen PZ, Li J, Yu DM, Huang D, Zhu XJ, Han Y, Chen J, Huang W, Chen YY, Gong QM, Jiang JH, Zhang DH, Zhang Y, Zhang JM, Zhang XX. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients. J Med Virol 2018;90:721-9. [PMID: 29247529 DOI: 10.1002/jmv.25010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
36 Tajiri K, Shimizu Y. New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol 2016; 8(21): 863-873 [PMID: 27478536 DOI: 10.4254/wjh.v8.i21.863] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
37 Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69-81. [PMID: 26112647 DOI: 10.1016/j.antiviral.2015.06.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 8.3] [Reference Citation Analysis]
38 Kosinska AD, Liu J, Lu M, Roggendorf M. Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck. Med Microbiol Immunol. 2015;204:103-114. [PMID: 25535101 DOI: 10.1007/s00430-014-0379-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
39 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 660] [Article Influence: 48.9] [Reference Citation Analysis]
40 Chevaliez S, Pawlotsky JM. Interferons and their use in persistent viral infections. Handb Exp Pharmacol 2009;:203-41. [PMID: 19048202 DOI: 10.1007/978-3-540-79086-0_8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
41 Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM, Lok AS. Present and future therapies of hepatitis B: From discovery to cure. Hepatology. 2015;62:1893-1908. [PMID: 26239691 DOI: 10.1002/hep.28025] [Cited by in Crossref: 193] [Cited by in F6Publishing: 180] [Article Influence: 32.2] [Reference Citation Analysis]
42 Dey D, Banerjee M. Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis. J Clin Transl Hepatol 2016;4:248-57. [PMID: 27777893 DOI: 10.14218/JCTH.2016.00025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
43 Tsuge M, Hiraga N, Uchida T, Kan H, Miyaki E, Masaki K, Ono A, Nakahara T, Abe-Chayama H, Zhang Y, Naswa MG, Kawaoka T, Miki D, Imamura M, Kawakami Y, Aikata H, Ochi H, Hayes CN, Chayama K. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection. J Gastroenterol 2016;51:1073-80. [PMID: 26943168 DOI: 10.1007/s00535-016-1189-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
44 Jinato T, Chuaypen N, Poomipak W, Praianantathavorn K, Makkoch J, Kiatbumrung R, Jampoka K, Tangkijvanich P, Payungporn S. Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment. Exp Biol Med (Maywood) 2016;241:1803-10. [PMID: 27190255 DOI: 10.1177/1535370216647184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
45 Höner Zu Siederdissen C, Cornberg M. Management of HBV and HBV/HDV-Associated Liver Cirrhosis. Visc Med 2016;32:86-94. [PMID: 27413725 DOI: 10.1159/000445518] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
46 Woo ASJ, Kwok R, Ahmed T. Alpha-interferon treatment in hepatitis B. Ann Transl Med. 2017;5:159. [PMID: 28480195 DOI: 10.21037/atm.2017.03.69] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
47 Kamezaki H, Kanda T, Arai M, Wu S, Nakamoto S, Chiba T, Maruyama H, Fujiwara K, Kanai F, Imazeki F. Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with Lamivudine. Int J Med Sci. 2013;10:567-574. [PMID: 23533048 DOI: 10.7150/ijms.5795] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
48 Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs. 2009;69:2167-2177. [PMID: 19852523 DOI: 10.2165/11319850-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
49 Meng Z, Chen Y, Lu M. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection. Front Immunol 2019;10:3127. [PMID: 32117201 DOI: 10.3389/fimmu.2019.03127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
50 Ahn J, Ko A, Jun EJ, Won M, Kim YK, Ju ES, Jeon ES, Lee H. Antiviral effects of small interfering RNA simultaneously inducing RNA interference and type 1 interferon in coxsackievirus myocarditis. Antimicrob Agents Chemother 2012;56:3516-23. [PMID: 22508300 DOI: 10.1128/AAC.06050-12] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
51 Ghany MG, Feld JJ, Chang KM, Chan HLY, Lok ASF, Visvanathan K, Janssen HLA. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol Hepatol 2020;5:406-17. [PMID: 32057301 DOI: 10.1016/S2468-1253(19)30344-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
52 Wang BX, Fish EN. The yin and yang of viruses and interferons. Trends Immunol 2012;33:190-7. [PMID: 22321608 DOI: 10.1016/j.it.2012.01.004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 8.8] [Reference Citation Analysis]
53 Wijesundara DK, Xi Y, Ranasinghe C. Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design. Front Immunol 2014;5:412. [PMID: 25221557 DOI: 10.3389/fimmu.2014.00412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
54 van Campenhout MJ, Janssen HL. How to achieve immune control in chronic hepatitis B? Hepatol Int. 2015;9:9-16. [PMID: 25788374 DOI: 10.1007/s12072-014-9571-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
55 Wei L, Wedemeyer H, Liaw YF, Chan HL, Piratvisuth T, Marcellin P, Jia J, Tan D, Chow WC, Brunetto MR, Diago M, Gurel S, Morozov V, He H, Zhu Y, Wat C, Surujbally B, Thompson AJ. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. PLoS One 2018;13:e0199198. [PMID: 30016335 DOI: 10.1371/journal.pone.0199198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
56 Chang JJ, Mohtashemi N, Bhattacharya D. Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era. Curr HIV/AIDS Rep 2018;15:172-81. [PMID: 29572624 DOI: 10.1007/s11904-018-0379-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
57 Lieber SR, Fried MW. Controversies in hepatitis C therapy: Reactivation of hepatitis B virus. Clin Liver Dis (Hoboken) 2017;10:87-92. [PMID: 31186893 DOI: 10.1002/cld.665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Liu F, Zou F, Wang X, Hu H, Hu P, Ren H. A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study. Virol J 2015;12:179. [PMID: 26527281 DOI: 10.1186/s12985-015-0409-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Li W, Shen X, Fu B, Guo C, Liu Y, Ye Y, Sun R, Li J, Tian Z, Wei H. KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B. Front Immunol 2017;8:1285. [PMID: 29075265 DOI: 10.3389/fimmu.2017.01285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Osborn M. Hepatitis B in HIV: available treatment options and approach to therapy. Curr Infect Dis Rep 2009;11:407-13. [PMID: 19698285 DOI: 10.1007/s11908-009-0057-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Matthews GV, Ali RJ, Avihingsanon A, Amin J, Hammond R, Bowden S, Lewin SR, Sasadeusz J, Littlejohn M, Locarnini SL, Ruxrungtham K, Dore GJ. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals. PLoS One 2013;8:e61297. [PMID: 23593455 DOI: 10.1371/journal.pone.0061297] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
62 Liao B, Wang Z, Lin S, Xu Y, Yi J, Xu M, Huang Z, Zhou Y, Zhang F, Hou J. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS One 2013;8:e78672. [PMID: 24205292 DOI: 10.1371/journal.pone.0078672] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
63 You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. World J Gastroenterol 2014; 20(37): 13293-13305 [PMID: 25309066 DOI: 10.3748/wjg.v20.i37.13293] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
64 Fujita K, Mimura S, Iwama H, Nakahara M, Oura K, Tadokoro T, Nomura T, Tani J, Yoneyama H, Morishita A, Oryu M, Himoto T, Nishitsuji H, Shimotohno K, Omata M, Masaki T. Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. Int J Mol Sci 2018;19:E1940. [PMID: 30004437 DOI: 10.3390/ijms19071940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
65 Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What’s the future holding for us? World J Gastroenterol 2015; 21(44): 12558-12575 [PMID: 26640332 DOI: 10.3748/wjg.v21.i44.12558] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
66 Bruder Costa J, Dufeu-Duchesne T, Leroy V, Bertucci I, Bouvier-Alias M, Pouget N, Brevot-Lutton O, Bourliere M, Zoulim F, Plumas J, Aspord C; ANRS HB06 PEGAN study group. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion. PLoS One 2016;11:e0158297. [PMID: 27348813 DOI: 10.1371/journal.pone.0158297] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
67 Karayiannis P. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012;2012:478631. [PMID: 24278700 DOI: 10.6064/2012/478631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
68 Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2:152-162. [PMID: 19669300 DOI: 10.1007/s12072-008-9056-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 5.5] [Reference Citation Analysis]
69 You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, Tang BZ, Huang ML, Ma YL, Chongsuvivatwong V, Sriplung H, Geater A, Qiao YW, Wu RX. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: A randomized controlled study. World J Gastroenterol 2006; 12(41): 6715-6721 [PMID: 17075991 DOI: 10.3748/wjg.v12.i41.6715] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
70 Tsukuda S, Watashi K, Iwamoto M, Suzuki R, Aizaki H, Okada M, Sugiyama M, Kojima S, Tanaka Y, Mizokami M. Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. J Biol Chem. 2015;290:5673-5684. [PMID: 25550158 DOI: 10.1074/jbc.M114.602540] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
71 Konerman MA, Lok AS. Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy? Clin Gastroenterol Hepatol 2015;13:386-9. [PMID: 25158927 DOI: 10.1016/j.cgh.2014.08.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
72 Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol. 2013;48:999-1005. [PMID: 23338486 DOI: 10.1007/s00535-012-0742-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
73 Hadziyannis SJ. Update on Hepatitis B Virus Infection: Focus on Treatment. J Clin Transl Hepatol 2014;2:285-91. [PMID: 26355326 DOI: 10.14218/JCTH.2014.00026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
74 Krastev ZA. The “return” of hepatitis B. World J Gastroenterol 2006; 12(44): 7081-7086 [PMID: 17131468 DOI: 10.3748/wjg.v12.i44.7081] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
75 Yoshida K, Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. Int J Mol Sci 2021;22:1456. [PMID: 33535672 DOI: 10.3390/ijms22031456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20:426-439, table of contents. [PMID: 17630333 DOI: 10.1128/cmr.00009-07] [Cited by in Crossref: 86] [Cited by in F6Publishing: 32] [Article Influence: 6.1] [Reference Citation Analysis]
77 Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
78 Hoa PT, Huy NT, Thu le T, Nga CN, Nakao K, Eguchi K, Chi NH, Hoang BH, Hirayama K. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2009;53:5134-5140. [PMID: 19770281 DOI: 10.1128/aac.00276-09] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
79 Xu Y, Wang X, Liu Z, Zhou C, Qi W, Jiao J, Yu F, Guo H, Zhao P, Wang J. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial. BMC Gastroenterol 2017;17:102. [PMID: 28854883 DOI: 10.1186/s12876-017-0657-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
80 Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance. Hepatol Int 2008;2:440-56. [PMID: 19669319 DOI: 10.1007/s12072-008-9105-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
81 Koh S, Bertoletti A. Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response? Med Microbiol Immunol 2015;204:87-94. [PMID: 25511870 DOI: 10.1007/s00430-014-0377-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
82 Yang S, Xing H, Wang Y, Hou J, Luo D, Xie Q, Ning Q, Ren H, Ding H, Sheng J, Wei L, Chen S, Fan X, Huang W, Pan C, Gao Z, Zhang J, Zhou B, Chen G, Wan M, Tang H, Wang G, Yang Y, Xu D, Dong P, Wang Q, Wang J, Bognar FA, Xu D, Cheng J. HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients. Virol J 2016;13:180. [PMID: 27793166 DOI: 10.1186/s12985-016-0640-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
83 Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007;356:1445-1454. [PMID: 17409326 DOI: 10.1056/nejmra065142] [Cited by in Crossref: 195] [Cited by in F6Publishing: 87] [Article Influence: 13.9] [Reference Citation Analysis]
84 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
85 Liu Y, Hussain M, Wong S, Fung SK, Yim HJ, Lok AS. A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol. 2007;45:553-558. [PMID: 17182753 DOI: 10.1128/jcm.00709-06] [Cited by in Crossref: 42] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
86 Muehlenbachs A, Nabasumba C, McGready R, Turyakira E, Tumwebaze B, Dhorda M, Nyehangane D, Nalusaji A, Nosten F, Guerin PJ, Piola P. Artemether-lumefantrine to treat malaria in pregnancy is associated with reduced placental haemozoin deposition compared to quinine in a randomized controlled trial. Malar J 2012;11:150. [PMID: 22554092 DOI: 10.1186/1475-2875-11-150] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
87 Arends JE, Lieveld FI, Ahmad S, Ustianowski A. New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review. Infect Dis Ther 2017;6:461-76. [PMID: 29071665 DOI: 10.1007/s40121-017-0173-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
88 Li J, Zhang X, Chen L, Zhang Z, Zhang J, Wang W, Wu M, Shi B, Zhang X, Kozlowski M, Hu Y, Yuan Z. Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients. Sci Rep. 2017;7:15658. [PMID: 29142236 DOI: 10.1038/s41598-017-15594-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
89 Lu M, Yao X, Xu Y, Lorenz H, Dahmen U, Chi H, Dirsch O, Kemper T, He L, Glebe D, Gerlich WH, Wen Y, Roggendorf M. Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol 2008;82:2598-603. [PMID: 18160442 DOI: 10.1128/JVI.01613-07] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
90 Du LY, Cui YL, Chen EQ, Cheng X, Liu L, Tang H. Correlation between the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in the resistance to interferon treatment. Virol J 2014;11:51. [PMID: 24636575 DOI: 10.1186/1743-422X-11-51] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
91 Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach. Gastroenterology. 2008;134:405-415. [PMID: 18242209 DOI: 10.1053/j.gastro.2007.11.036] [Cited by in Crossref: 163] [Cited by in F6Publishing: 151] [Article Influence: 11.6] [Reference Citation Analysis]
92 Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012;13:663-76. [PMID: 22815098 DOI: 10.1007/s10198-012-0413-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
93 Delicio AM, Abati PA, Vigani AG. Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report. J Venom Anim Toxins Incl Trop Dis 2013;19:31. [PMID: 24325818 DOI: 10.1186/1678-9199-19-31] [Reference Citation Analysis]
94 Bzowej NH. Optimal Management of the Hepatitis B Patient Who Desires Pregnancy or Is Pregnant. Curr Hepat Rep. 2012;11:82-89. [PMID: 22707918 DOI: 10.1007/s11901-012-0130-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
95 Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 2015;61:712-21. [PMID: 25048716 DOI: 10.1002/hep.27323] [Cited by in Crossref: 102] [Cited by in F6Publishing: 103] [Article Influence: 17.0] [Reference Citation Analysis]
96 Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis. 2011;52:1294-1306. [PMID: 21540206 DOI: 10.1093/cid/cir199] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
97 Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J;  Chronic Hepatitis B Study Consortium. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016;65:313-320. [PMID: 25586058 DOI: 10.1136/gutjnl-2014-308546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 12.0] [Reference Citation Analysis]
98 Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, Heim MH. Inhibition of alpha interferon signaling by hepatitis B virus. J Virol. 2007;81:159-165. [PMID: 17065208 DOI: 10.1128/jvi.01292-06] [Cited by in Crossref: 83] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
99 Seo Y, Yano Y. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection. World J Gastroenterol 2014; 20(37): 13284-13292 [PMID: 25309065 DOI: 10.3748/wjg.v20.i37.13284] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
100 Zhang Y, Wang YT, Luo JX, Hu XY, Yang F, Lin W, Liang X, Zhao BJ, Zhang S, Chen YY. Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20-30 Times the ULN). Evid Based Complement Alternat Med 2019;2019:7260369. [PMID: 30949222 DOI: 10.1155/2019/7260369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Campagna MR, Liu F, Mao R, Mills C, Cai D, Guo F, Zhao X, Ye H, Cuconati A, Guo H. Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol. 2013;87:6931-6942. [PMID: 23576513 DOI: 10.1128/jvi.00582-13] [Cited by in Crossref: 105] [Cited by in F6Publishing: 54] [Article Influence: 13.1] [Reference Citation Analysis]
102 Ghosh S, Chakraborty A, Banerjee S. Persistence of Hepatitis B Virus Infection: A Multi-Faceted Player for Hepatocarcinogenesis. Front Microbiol 2021;12:678537. [PMID: 34526974 DOI: 10.3389/fmicb.2021.678537] [Reference Citation Analysis]
103 Su TH, Liu CJ. Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. Gut Liver 2017;11:590-603. [PMID: 28494575 DOI: 10.5009/gnl16215] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
104 Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection - an update. Microb Cell 2016;3:420-37. [PMID: 28357379 DOI: 10.15698/mic2016.09.527] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
105 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 7.8] [Reference Citation Analysis]
106 Chen H, Chuai X, Deng Y, Wen B, Wang W, Xiong S, Ruan L, Tan W. Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine. PLoS One 2012;7:e43730. [PMID: 22970140 DOI: 10.1371/journal.pone.0043730] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
107 Domagalski K, Pawłowska M, Zaleśna A, Tyczyno M, Skorupa-Kłaput M, Tretyn A, Halota W. The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection. Eur J Clin Microbiol Infect Dis 2014;33:2025-33. [PMID: 24924923 DOI: 10.1007/s10096-014-2172-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
108 Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH;  American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283. [PMID: 26566064 DOI: 10.1002/hep.28156] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1064] [Article Influence: 193.2] [Reference Citation Analysis]
109 Thanapirom K, Suksawatamnuay S, Sukeepaisarnjareon W, Tanwandee T, Charatcharoenwitthaya P, Thongsawat S, Leerapun A, Piratvisuth T, Boonsirichan R, Bunchorntavakul C, Pattanasirigool C, Pornthisarn B, Tantipanichtheerakul S, Sripariwuth E, Jeamsripong W, Sanpajit T, Poovorawan Y, Komolmit P. Genetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: A multicenter study. PLoS One 2017;12:e0173263. [PMID: 28296915 DOI: 10.1371/journal.pone.0173263] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
110 Wi CI, Kim WR, Gross JB, Stadheim LM, Poterucha JJ. Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B. Gut Liver 2016;10:611-6. [PMID: 26190580 DOI: 10.5009/gnl14256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
111 Enomoto M, Nishiguchi S, Tamori A, Kobayashi S, Sakaguchi H, Shiomi S, Kim SR, Enomoto H, Saito M, Imanishi H. Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol. 2013;48:397-404. [PMID: 22850869 DOI: 10.1007/s00535-012-0645-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
112 Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, Reaiche-Miller G, Finnie J, Werner M, Broering R, Schlaak JF, Vaillant A, Jilbert AR. Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection. PLoS One. 2015;10:e0140909. [PMID: 26560490 DOI: 10.1371/journal.pone.0140909] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
113 Abaalkhail F, Elsiesy H, AlOmair A, Alghamdi MY, Alalwan A, AlMasri N, Al-Hamoudi W; Saudi Association for the Study of Liver Diseases and Transplantation (SASLT). SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol 2014;20:5-25. [PMID: 24496154 DOI: 10.4103/1319-3767.126311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
114 Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B: Lamivudine resistance. Hepatol Int. 2008;2:440-456. [PMID: 19669319 DOI: 10.1007/s12072-008-9105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Tsuge M, Uchida T, Hiraga N, Kan H, Makokha GN, Abe-Chayama H, Miki D, Imamura M, Ochi H, Hayes CN, Shimozono R, Iwamura T, Narumi H, Suzuki T, Kainoh M, Taniguchi T, Chayama K. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus. Antimicrob Agents Chemother. 2017;61. [PMID: 28373196 DOI: 10.1128/aac.00183-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
116 Lau G, Marcellin P, Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int 2007;1:316-25. [PMID: 19669356 DOI: 10.1007/s12072-007-9006-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
117 Marcellin P, Xie Q, Woon Paik S, Flisiak R, Piratvisuth T, Petersen J, Asselah T, Cornberg M, Ouzan D, Foster GR, Papatheodoridis G, Messinger D, Regep L, Bakalos G, Alshuth U, Lampertico P, Wedemeyer H. Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. PLoS One 2020;15:e0230893. [PMID: 32275726 DOI: 10.1371/journal.pone.0230893] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Lu HY, Zhuang LW, Yu YY, Ivan H, Si CW, Zeng Z, Li J, Hou DM, Chen XY, Han ZH, Chen Y. Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol 2007; 13(20): 2878-2882 [PMID: 17569128 DOI: 10.3748/wjg.v13.i20.2878] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
119 Marathe BM, Wong SS, Vogel P, Garcia-Alcalde F, Webster RG, Webby RJ, Najera I, Govorkova EA. Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice. Sci Rep 2016;6:26742. [PMID: 27221530 DOI: 10.1038/srep26742] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
120 Al Ashgar H, Peedikayil MC, Al Quaiz M, Al Sohaibani F, Al Fadda A, Khan MQ, Thoralsson E, Al Thawadi S, Al Jedai A, Al Kahtani K. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study. Saudi J Gastroenterol 2017;23:190-8. [PMID: 28611343 DOI: 10.4103/sjg.SJG_541_16] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
121 Uchida T, Imamura M, Hayes CN, Hiraga N, Kan H, Tsuge M, Abe-Chayama H, Zhang Y, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice. Antimicrob Agents Chemother 2017;61:e00725-17. [PMID: 28696237 DOI: 10.1128/AAC.00725-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
122 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 659] [Article Influence: 77.2] [Reference Citation Analysis]
123 Han SH. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B. Drugs 2006;66:1831-51. [PMID: 17040114 DOI: 10.2165/00003495-200666140-00005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
124 Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, Möller I, Seiz P, Glebe D, Wang B, Yang D, Lu M, Roggendorf M. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014;10:e1003856. [PMID: 24391505 DOI: 10.1371/journal.ppat.1003856] [Cited by in Crossref: 166] [Cited by in F6Publishing: 162] [Article Influence: 23.7] [Reference Citation Analysis]
125 丁洋, 吴发玲, 盛秋菊, 赵连荣, 夏婷婷, 王静艳, 石理兰, 王淑兰, 单红, 安萍, 段红岩, 窦晓光. 聚乙二醇干扰素α-2a联合阿德福韦酯对HBeAg阳性慢性乙型肝炎的治疗. 世界华人消化杂志 2012; 20(22): 2036-2042 [DOI: 10.11569/wcjd.v20.i22.2036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Yang JF, Kao YH, Dai CY, Huang JF, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chuang WL, Yu ML. Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan. Hepatol Int 2010;4:732-40. [PMID: 21286344 DOI: 10.1007/s12072-010-9208-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
127 Huang YC, Jiang CM, Chen YJ, Chen YY. Pectinesterase Inhibitor from Jelly Fig (Ficus awkeotsang Makino) Achene Inhibits Surface Antigen Expression by Human Hepatitis B Virus. Evid Based Complement Alternat Med 2013;2013:434823. [PMID: 24302965 DOI: 10.1155/2013/434823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
128 Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458-465. [PMID: 16557381 DOI: 10.1007/s00432-006-0091-y] [Cited by in Crossref: 156] [Cited by in F6Publishing: 149] [Article Influence: 10.4] [Reference Citation Analysis]
129 Liang KH, Lin CL, Hsu CW, Lai MW, Chien RN, Yeh CT. UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy. Sci Rep 2016;6:34088. [PMID: 27665939 DOI: 10.1038/srep34088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
130 Müller C. Chronic Hepatitis B and C--current treatment and future therapeutic prospects. Wien Med Wochenschr. 2006;156:391-396. [PMID: 16937041 DOI: 10.1007/s10354-006-0314-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
131 Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. [PMID: 29405329 DOI: 10.1002/hep.29800] [Cited by in Crossref: 1129] [Cited by in F6Publishing: 997] [Article Influence: 376.3] [Reference Citation Analysis]
132 Kao JH. Molecular epidemiology of hepatitis B virus. Korean J Intern Med 2011;26:255-61. [PMID: 22016585 DOI: 10.3904/kjim.2011.26.3.255] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
133 Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol Rep. 2007;9:14-22. [PMID: 17335673 DOI: 10.1007/s11894-008-0016-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
134 Ezzikouri S, Kayesh MEH, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines (Basel) 2020;8:E216. [PMID: 32403281 DOI: 10.3390/vaccines8020216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
135 Sonneveld MJ, Janssen HL. Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010;9:91-98. [PMID: 20461129 DOI: 10.1007/s11901-010-0041-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
136 Wu IC, Liu WC, Chiu YC, Chiu HC, Cheng PN, Chang TT. Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss. Microorganisms 2021;9:1146. [PMID: 34073483 DOI: 10.3390/microorganisms9061146] [Reference Citation Analysis]
137 Sonneveld MJ, Zoutendijk R, Flink HJ, Zwang L, Hansen BE, Janssen HL. Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. Clin Infect Dis 2013;56:100-5. [PMID: 23042976 DOI: 10.1093/cid/cis859] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
138 Xiong YL, Li H, Liu F, Zhang D, Ren H, Hu P. Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B. Hepat Mon 2016;16:e35357. [PMID: 27257427 DOI: 10.5812/hepatmon.35357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
139 Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8:275-284. [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33] [Cited by in Crossref: 171] [Cited by in F6Publishing: 164] [Article Influence: 17.1] [Reference Citation Analysis]
140 Gong L, Han Y, Chen L, Liu F, Hao P, Sheng J, Li XH, Yu DM, Gong QM, Tian F. Comparison of next-generation sequencing and clone-based sequencing in analysis of hepatitis B virus reverse transcriptase quasispecies heterogeneity. J Clin Microbiol. 2013;51:4087-4094. [PMID: 24088859 DOI: 10.1128/jcm.01723-13] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 4.1] [Reference Citation Analysis]
141 Li M, Zhang L, Lu Y, Chen Q, Lu H, Sun F, Zeng Z, Wan G, Zhao L, Xie Y. Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a. Virol Sin 2021;36:311-20. [PMID: 32975731 DOI: 10.1007/s12250-020-00290-7] [Reference Citation Analysis]
142 Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011;5:644-53. [PMID: 21484123 DOI: 10.1007/s12072-011-9261-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
143 Marugán RB, Garzón SG. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol 2009; 15(4): 423-430 [PMID: 19152446 DOI: 10.3748/wjg.15.423] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
144 Zhang K, Cao H, Liang J, Shu X, Sun H, Li G, Xu Q. CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study. Medicine (Baltimore). 2016;95:e4471. [PMID: 27495085 DOI: 10.1097/md.0000000000004471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
145 Tan Y, Ye Y, Zhou X, Chen L, Wen D. Age as a predictor of significant fibrosis features in HBeAg-negative chronic hepatitis B virus infection with persistently normal alanine aminotransferase. PLoS One. 2015;10:e0123452. [PMID: 25885705 DOI: 10.1371/journal.pone.0123452] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
146 Ogawa E, Furusyo N, Nguyen MH. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. Drug Des Devel Ther 2017;11:3197-204. [PMID: 29158666 DOI: 10.2147/DDDT.S126742] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
147 Ghany MG, Feld JJ, Zhao X, Heller T, Doo E, Rotman Y, Nagabhyru P, Koh C, Kleiner DE, Wright EC, Liang TJ, Hoofnagle JH. Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. Aliment Pharmacol Ther 2012;35:1027-35. [PMID: 22449251 DOI: 10.1111/j.1365-2036.2012.05059.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 0.2] [Reference Citation Analysis]
148 Liem KS, van Campenhout MJH, Xie Q, Brouwer WP, Chi H, Qi X, Chen L, Tabak F, Hansen BE, Janssen HLA. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2019;49:448-456. [PMID: 30689258 DOI: 10.1111/apt.15098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
149 Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity 2019;50:907-23. [PMID: 30995506 DOI: 10.1016/j.immuni.2019.03.025] [Cited by in Crossref: 267] [Cited by in F6Publishing: 251] [Article Influence: 133.5] [Reference Citation Analysis]
150 Anikhindi SA, Kumar A, Sharma P, Singla V, Bansal N, Arora A. Ideal Cure for Hepatitis B Infection: The Target is in Sight. J Clin Exp Hepatol 2018;8:188-94. [PMID: 29892183 DOI: 10.1016/j.jceh.2017.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Wu HL, Hsiao TH, Chen PJ, Wong SH, Kao JH, Chen DS, Lu JY, Lu TP, Chen Y, Chuang EY, Tu HC, Liu CJ. Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients. Sci Rep. 2016;6:31349. [PMID: 27546197 DOI: 10.1038/srep31349] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
152 Wang D, Fu B, Shen X, Guo C, Liu Y, Zhang J, Sun R, Ye Y, Li J, Tian Z, Wei H. Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy. Signal Transduct Target Ther 2021;6:376. [PMID: 34737296 DOI: 10.1038/s41392-021-00776-0] [Reference Citation Analysis]
153 Wu YL, Shen CL, Chen XY. Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. World J Clin Cases 2019; 7(14): 1784-1794 [PMID: 31417924 DOI: 10.12998/wjcc.v7.i14.1784] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
154 Cui XX, Yang X, Wang HJ, Rong XY, Jing S, Xie YH, Huang DF, Zhao C. Luteolin-7-O-Glucoside Present in Lettuce Extracts Inhibits Hepatitis B Surface Antigen Production and Viral Replication by Human Hepatoma Cells in Vitro. Front Microbiol 2017;8:2425. [PMID: 29270164 DOI: 10.3389/fmicb.2017.02425] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
155 Umar M, Hamama-Tul-Bushra, Umar S, Khan HA. HBV perinatal transmission. Int J Hepatol 2013;2013:875791. [PMID: 23738081 DOI: 10.1155/2013/875791] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
156 Lin Z, Zhang J, Ma X, Yang S, Tian N, Lin X, Zhou S, Liu L, Gao Y. The Role of Interferon Lambda 3 Genetic Polymorphisms in Response to Interferon Therapy in Chronic Hepatitis B Patients: An Updated Meta-Analysis. Hepat Mon 2016;16:e37534. [PMID: 27656234 DOI: 10.5812/hepatmon.37534] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
157 Wu D, Wang P, Han M, Chen Y, Chen X, Xia Q, Yan W, Wan X, Zhu C, Xie Q, Jiang J, Wei L, Tan D, Dou X, Yu Y, Hou J, Luo X, Ning Q. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol Int. 2019;13:573-586. [PMID: 31172415 DOI: 10.1007/s12072-019-09956-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
158 Dozier JK, Distefano MD. Site-Specific PEGylation of Therapeutic Proteins. Int J Mol Sci 2015;16:25831-64. [PMID: 26516849 DOI: 10.3390/ijms161025831] [Cited by in Crossref: 142] [Cited by in F6Publishing: 121] [Article Influence: 23.7] [Reference Citation Analysis]
159 Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2006;66:1605-122; discussion 1605-122;. [PMID: 16956310 DOI: 10.2165/00003495-200666120-00009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
160 Wang H, Liu K, Fang BAM, Wu H, Li F, Xiang X, Tang W, Zhao G, Lin L, Bao S, Xie Q. Identification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening. Cell Biosci 2015;5:66. [PMID: 26640654 DOI: 10.1186/s13578-015-0059-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
161 Wang Q, Li H, Ding D, Peng M, Ren H, Hu P. Upgrade Combination Response Is Limited by Prolonged Nucelos(t)ide Analogue Therapy in HBeAg-positive Chronic Hepatitis B: A Real-life Study. J Clin Transl Hepatol 2018;6:11-7. [PMID: 29577027 DOI: 10.14218/JCTH.2017.00020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
162 Piratvisuth T, Lau G, Chao YC, Jin R, Chutaputti A, Zhang QB, Tanwandee T, Button P, Popescu M. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int. 2008;2:102-110. [PMID: 19669285 DOI: 10.1007/s12072-007-9022-5] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 4.6] [Reference Citation Analysis]
163 Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, Roggendorf M. Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog 2013;9:e1003391. [PMID: 23785279 DOI: 10.1371/journal.ppat.1003391] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 9.4] [Reference Citation Analysis]
164 Masaki K, Suzuki F, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection. Virol J 2015;12:225. [PMID: 26700861 DOI: 10.1186/s12985-015-0453-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
165 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Brooks J, Gelson W, Rushbrook SM. Therapeutic advances in the management of chronic hepatitis B infection. Ther Adv Chronic Dis 2013;4:157-66. [PMID: 23819019 DOI: 10.1177/2040622313484647] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
167 Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J. Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? Bull World Health Organ 2010;88:66-73. [PMID: 20428355 DOI: 10.2471/BLT.08.065722] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
168 Kelly D. Viral hepatitis B and C in children. J R Soc Med 2006;99:353-7. [PMID: 16816265 DOI: 10.1258/jrsm.99.7.353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
169 Kim SR, Yang J, Kudo M, Hino O. Recent advances in the management of chronic hepatitis B. Hepat Mon 2011;11:601-11. [PMID: 22140383 DOI: 10.5812/kowsar.1735143x.657] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
170 Kim HY, Kwon HD, Jang TS, Lim J, Lee HS. Mathematical modeling of triphasic viral dynamics in patients with HBeAg-positive chronic hepatitis B showing response to 24-week clevudine therapy. PLoS One 2012;7:e50377. [PMID: 23209728 DOI: 10.1371/journal.pone.0050377] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
171 Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y, Li Y, Liu Y, Liu G, Mao D, Chi X, Tang H, Li X, Xie Y, Chen X, Jiang J, Zhao P, Hou J, Gao Z, Fan H, Ding J, Zhang D, Ren H. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol 2018;6:25-34. [PMID: 29577029 DOI: 10.14218/JCTH.2017.00072] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 9.7] [Reference Citation Analysis]
172 Guo JT, Guo H. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Res. 2015;122:91-100. [PMID: 26272257 DOI: 10.1016/j.antiviral.2015.08.005] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 13.8] [Reference Citation Analysis]
173 Fu LL, Liu J, Chen Y, Wang FT, Wen X, Liu HQ, Wang MY, Ouyang L, Huang J, Bao JK. In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy. Cell Prolif. 2014;47:326-335. [PMID: 24965018 DOI: 10.1111/cpr.12117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
174 Hagiwara S, Nishida N, Kudo M. Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon. World J Hepatol 2015; 7(23): 2427-2431 [PMID: 26483864 DOI: 10.4254/wjh.v7.i23.2427] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
175 Abdel-Hady M, Kelly D. Chronic hepatitis B in children and adolescents: epidemiology and management. Paediatr Drugs 2013;15:311-7. [PMID: 23529864 DOI: 10.1007/s40272-013-0010-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
176 Tana MM, Ghany MG. Hepatitis B virus treatment: Management of antiviral drug resistance. Clin Liver Dis (Hoboken) 2013;2:24-8. [PMID: 30992816 DOI: 10.1002/cld.162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Tong MJ, Pan CQ, Hann HW, Kowdley KV, Han SH, Min AD, Leduc TS. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci. 2011;56:3143-3162. [PMID: 21935699 DOI: 10.1007/s10620-011-1841-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
178 Lacey LF, Gane E. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat 2007;14:751-66. [PMID: 17927611 DOI: 10.1111/j.1365-2893.2007.00865.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
179 Kanda T. No additive effects of peginterferon on the short-term improvement of liver histology by entecavir monotherapy in chronic hepatitis B patients. Hepatol Int 2021;15:579-81. [PMID: 33900575 DOI: 10.1007/s12072-021-10191-w] [Reference Citation Analysis]
180 He XS, Nanda S, Ji X, Calderon-Rodriguez GM, Greenberg HB, Liang TJ. Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes. J Interferon Cytokine Res 2010;30:311-20. [PMID: 20038212 DOI: 10.1089/jir.2009.0082] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
181 Jr GP, Kim JH, Suh JS, Sharp VL. Predictors of loss of hepatitis B surface antigen in HIV-infected patients. World J Gastroenterol 2010; 16(9): 1093-1096 [PMID: 20205279 DOI: 10.3748/wjg.v16.i9.1093] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
182 Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008;26:937-49. [PMID: 18850763 DOI: 10.2165/00019053-200826110-00006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
183 Leemans W, Janssen H, de Man R. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007; 13(18): 2554-2567 [PMID: 17552002 DOI: 10.3748/wjg.v13.i18.2554] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
184 Sonneveld MJ, Brouwer WP, Hansen BE, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Chien RN, Choi H, de Knegt RJ, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Man RA, Janssen HLA; SONIC-B Study Group. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. Aliment Pharmacol Ther 2020;52:1399-406. [PMID: 32886813 DOI: 10.1111/apt.16067] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Shen T, Yan XM. Hepatitis B virus genetic mutations and evolution in liver diseases. World J Gastroenterol 2014; 20(18): 5435-5441 [PMID: 24833874 DOI: 10.3748/wjg.v20.i18.5435] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
186 Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20(20): 6262-6278 [PMID: 24876747 DOI: 10.3748/wjg.v20.i20.6262] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 81] [Article Influence: 12.1] [Reference Citation Analysis]
187 Tan ZM, Sun BC. Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World J Gastroenterol 2013; 19(47): 8895-8901 [PMID: 24379613 DOI: 10.3748/wjg.v19.i47.8895] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
188 Chang J, Guo F, Zhao X, Guo JT. Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharm Sin B. 2014;4:248-257. [PMID: 26579392 DOI: 10.1016/j.apsb.2014.05.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
189 Brakenhoff SM, de Man RA, Boonstra A, van Campenhout MJH, de Knegt RJ, van Bömmel F, van der Eijk AA, Berg T, Hansen BE, Janssen HLA, Sonneveld MJ. Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. Aliment Pharmacol Ther 2021;53:314-20. [PMID: 33222190 DOI: 10.1111/apt.16172] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
190 Yamamiya D, Mizukoshi E, Kaji K, Terashima T, Kitahara M, Yamashita T, Arai K, Fushimi K, Honda M, Kaneko S. Immune responses of human T lymphocytes to novel hepatitis B virus-derived peptides. PLoS One 2018;13:e0198264. [PMID: 29856876 DOI: 10.1371/journal.pone.0198264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
191 Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura YI, Dohi T, Shuno Y, Yano H, Mizokami M. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut 2018;67:362-71. [PMID: 27789659 DOI: 10.1136/gutjnl-2016-312653] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 15.2] [Reference Citation Analysis]
192 Jia W, Zhu MQ, Qi X, Wang T, Wen X, Chen PD, Fan QQ, Zhang WH, Zhang JM. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. Virol J 2019;16:61. [PMID: 31064399 DOI: 10.1186/s12985-019-1152-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
193 Chang TT, Suh DJ. Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int 2008;2:19-27. [PMID: 19669295 DOI: 10.1007/s12072-008-9059-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
194 Lu HY, Zhuang LW, Yu YY, Si CW, Li J, Zhang JJ, Zeng Z, Chen XY, Han ZH, Chen Y. Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol 2008; 14(8): 1268-1273 [PMID: 18300356 DOI: 10.3748/wjg.14.1268] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
195 Wang G, Guan J, Khan NU, Li G, Shao J, Zhou Q, Xu L, Huang C, Deng J, Zhu H, Chen Z. Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus. Gut Pathog 2021;13:22. [PMID: 33845868 DOI: 10.1186/s13099-021-00421-9] [Reference Citation Analysis]
196 Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, Shi JJ, Zhang X, Jia XL, Dang SS. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study. World J Gastroenterol 2020; 26(13): 1525-1539 [PMID: 32308352 DOI: 10.3748/wjg.v26.i13.1525] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
197 Byrne R, Carey I, Agarwal K. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Therap Adv Gastroenterol 2018;11:1756284818786108. [PMID: 30034532 DOI: 10.1177/1756284818786108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
198 Feld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network. Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. Hepatology 2019;69:2338-48. [PMID: 30549279 DOI: 10.1002/hep.30417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
199 Domagalski K, Pawłowska M, Zaleśna A, Pilarczyk M, Rajewski P, Halota W, Tretyn A. Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus. World J Gastroenterol 2016; 22(41): 9186-9195 [PMID: 27895405 DOI: 10.3748/wjg.v22.i41.9186] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
200 Okanoue T, Minami M. Update of research and management of hepatitis B. J Gastroenterol 2006;41:107-18. [PMID: 16568369 DOI: 10.1007/s00535-006-1774-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
201 Chen CC, Wang PC, Chang HW, Chen CF. Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation. J Viral Hepat. 2012;19:161-172. [PMID: 22329370 DOI: 10.1111/j.1365-2893.2011.01469] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
202 Shamliyan TA, Johnson JR, MacDonald R, Shaukat A, Yuan JM, Kane RL, Wilt TJ. Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 2011;26:326-39. [PMID: 21203860 DOI: 10.1007/s11606-010-1569-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
203 Takkenberg B, de Bruijne J, Weegink C, Jansen P, Reesink H. Novel therapies in hepatitis B and C. Curr Gastroenterol Rep 2008;10:81-90. [PMID: 18417047 DOI: 10.1007/s11894-008-0013-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
204 Guillot C, Martel N, Berby F, Bordes I, Hantz O, Blanchet M, Sureau C, Vaillant A, Chemin I. Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes. PLoS One 2017;12:e0179697. [PMID: 28636622 DOI: 10.1371/journal.pone.0179697] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
205 Piratvisuth T. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. Hepatol Int 2008;2:140-6. [PMID: 19669298 DOI: 10.1007/s12072-008-9046-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
206 Reijnders JG, LA Janssen H. New approaches in the management of chronic hepatitis B: role of tenofovir. Infect Drug Resist 2009;2:13-26. [PMID: 21694884 DOI: 10.2147/idr.s3918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
207 Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14(45): 6902-6910 [PMID: 19058323 DOI: 10.3748/wjg.14.6902] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
208 Lau DT, Bleibel W. Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol. 2008;1:61-75. [PMID: 21180515 DOI: 10.1177/1756283x08093944] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
209 Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis. 2011;11:165. [PMID: 21651820 DOI: 10.1186/1471-2334-11-165] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
210 Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J 2021;18:114. [PMID: 34082765 DOI: 10.1186/s12985-021-01589-x] [Reference Citation Analysis]
211 Stein LL, Loomba R. Drug targets in hepatitis B virus infection. Infect Disord Drug Targets 2009;9:105-16. [PMID: 19275699 DOI: 10.2174/187152609787847677] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
212 Okushin H, Ohnishi T, Morii K, Uesaka K, Yuasa S. Short-term intravenous interferon therapy for chronic hepatitis B. World J Gastroenterol 2008; 14(19): 3038-3043 [PMID: 18494055 DOI: 10.3748/wjg.14.3038] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
213 Guo Y, Lu H, Xu L, Idris NFB, Li Y, Hu J, Huang A, Tu Z. The response of hepatitis B virus genotype to interferon is associated with a mutation in the interferon-stimulated response element. Medicine (Baltimore). 2019;98:e18442. [PMID: 31861015 DOI: 10.1097/md.0000000000018442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
214 Reinharz V, Ishida Y, Tsuge M, Durso-Cain K, Chung TL, Tateno C, Perelson AS, Uprichard SL, Chayama K, Dahari H. Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. J Virol 2021;95:e0049220. [PMID: 33910953 DOI: 10.1128/JVI.00492-20] [Reference Citation Analysis]
215 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 120] [Article Influence: 12.1] [Reference Citation Analysis]
216 Ayoub WS, Cohen E. Hepatitis B Management in the Pregnant Patient: An Update. J Clin Transl Hepatol 2016;4:241-7. [PMID: 27777892 DOI: 10.14218/JCTH.2016.00014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
217 Goh ZY, Ren EC, Ko HL. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B. World J Gastroenterol 2021; 27(14): 1369-1391 [PMID: 33911462 DOI: 10.3748/wjg.v27.i14.1369] [Reference Citation Analysis]
218 Wang S, Huang D, Sun S, Ma W, Zhen Q. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa. Virol J 2011;8:28. [PMID: 21251301 DOI: 10.1186/1743-422X-8-28] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
219 Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 2009;44:470-5. [DOI: 10.1007/s00535-009-0024-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
220 Ying SY, Hu YR, Gao GS, Lou KH, Huang Z. Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis. Front Med (Lausanne) 2021;8:691365. [PMID: 34307418 DOI: 10.3389/fmed.2021.691365] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X, Ren H. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2018;6:1-10. [PMID: 29577026 DOI: 10.14218/JCTH.2017.00073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
222 Mealing S, Ghement I, Hawkins N, Scott DA, Lescrauwaet B, Watt M, Thursz M, Lampertico P, Mantovani L, Morais E, Bregman B, Cucherat M. The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. Syst Rev 2014;3:21. [PMID: 24602249 DOI: 10.1186/2046-4053-3-21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
223 Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther 2018;47:1181-200. [PMID: 29479728 DOI: 10.1111/apt.14577] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
224 Rehermann B, Thimme R. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection. Gastroenterology 2019;156:369-83. [PMID: 30267712 DOI: 10.1053/j.gastro.2018.08.061] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 16.7] [Reference Citation Analysis]
225 Li Y, Zhu C, Wang F, Zhu T, Li J, Liu S, Xiao F. Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection. Mediators Inflamm 2016;2016:3894816. [PMID: 28077916 DOI: 10.1155/2016/3894816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
226 Wong WW, Woo G, Heathcote EJ, Krahn M. Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol 2013;27:137-47. [PMID: 23516678 DOI: 10.1155/2013/924640] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
227 Lee SW, Lee TY, Yang SS, Peng YC, Yeh HZ, Chang CS. Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals. Gastroenterology Res 2018;11:124-9. [PMID: 29707079 DOI: 10.14740/gr971w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
228 Toscano AL, Corrêa MC. Evolution of hepatitis B serological markers in HIV coinfected patients: a case study. Rev Saude Publica 2017;51:24. [PMID: 28380208 DOI: 10.1590/S1518-8787.2017051006693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
229 Kawanaka M, Nishino K, Nakamura J, Oka T, Urata N, Goto D, Suehiro M, Kawamoto H, Kudo M, Yamada G. Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy. Liver Cancer. 2014;3:41-52. [PMID: 24804176 DOI: 10.1159/000343857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
230 Ma A, Motyka B, Gutfreund K, Shi YE, George R. A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B. Hum Vaccin Immunother. 2020;16:756-778. [PMID: 31687879 DOI: 10.1080/21645515.2019.1689080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
231 Miyauchi T, Kanda T, Shinozaki M, Kamezaki H, Wu S, Nakamoto S, Kato K, Arai M, Mikami S, Sugiura N. Efficacy of lamivudine or entecavir against virological rebound after achieving HBV DNA negativity in chronic hepatitis B patients. Int J Med Sci. 2013;10:647-652. [PMID: 23569428 DOI: 10.7150/ijms.5904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
232 Rudin D, Shah SM, Kiss A, Wetz RV, Sottile VM. Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver Int 2007;27:1185-93. [PMID: 17919229 DOI: 10.1111/j.1478-3231.2007.01580.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
233 Chotiyaputta W, Lok ASF. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009;6:453-62. [DOI: 10.1038/nrgastro.2009.107] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 9.1] [Reference Citation Analysis]
234 Keating GM. Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B. Drugs 2009;69:2633-60. [PMID: 19943712 DOI: 10.2165/11203660-000000000-00000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
235 Flisiak R, Halota W, Jaroszewicz J, Juszczyk J, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tomasiewicz K, Wawrzynowicz-Syczewska M; Polish Group of Experts for HBV. Recommendations for the treatment of hepatitis B in 2017. Clin Exp Hepatol 2017;3:35-46. [PMID: 28856289 DOI: 10.5114/ceh.2017.67626] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
236 Madan K, Tyagi P. Hepatitis B virus genotyping: is the time ripe for routine clinical use? J Clin Exp Hepatol 2012;2:174-80. [PMID: 25755425 DOI: 10.1016/S0973-6883(12)60105-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
237 Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007;1:415-430. [PMID: 19669337 DOI: 10.1007/s12072-007-9033-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 4.8] [Reference Citation Analysis]
238 Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. J Gastroenterol. 2018;53:247-257. [PMID: 28634723 DOI: 10.1007/s00535-017-1360-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
239 Lu F, Wang J, Chen X, Xu D, Xia N. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Front Med 2017;11:502-8. [PMID: 29170915 DOI: 10.1007/s11684-017-0590-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
240 Chen L, Lin L, Zhou H, Tang W, Wang H, Cai W, Bao S, Guo S, Xie Q. Peginterferon and Entecavir Combination Therapy Improves Outcome of Non-Early Response Hepatitis B e Antigen-Positive Patients. Open Forum Infect Dis 2020;7:ofaa462. [PMID: 33889654 DOI: 10.1093/ofid/ofaa462] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
241 Forde KA, Tanapanpanit O, Reddy KR. Hepatitis B and C in African Americans: current status and continued challenges. Clin Gastroenterol Hepatol 2014;12:738-48. [PMID: 23811241 DOI: 10.1016/j.cgh.2013.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
242 Flink HJ, Buster EH, Merican I, Nevens F, Kitis G, Cianciara J, de Vries RA, Hansen BE, Schalm SW, Janssen HL. Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B. Gut 2007;56:1485-6. [PMID: 17872587 DOI: 10.1136/gut.2007.125633] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
243 Vassiliadis T, Patsiaoura K, Tziomalos K, Gkiourtzis T, Giouleme O, Grammatikos N, Rizopoulou D, Nikolaidis N, Katsinelos P, Orfanou-Koumerkeridou E, Eugenidis N. Pegylated IFN-α 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2006; 12(15): 2417-2422 [PMID: 16688836 DOI: 10.3748/wjg.v12.i15.2417] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
244 Cho EJ, Lee JH, Yoon JH. Combination of Pegylated Interferon and Nucleos(t)ide Therapy: Toward a Cure of Hepatitis B Virus Infection? Gut Liver 2016;10:497-8. [PMID: 26198336 DOI: 10.5009/gnl15307] [Reference Citation Analysis]
245 Bhattacharya D, Thio CL. Review of hepatitis B therapeutics. Clin Infect Dis. 2010;51:1201-1208. [PMID: 20954965 DOI: 10.1086/656624] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 5.1] [Reference Citation Analysis]
246 Hu Y, Ye YZ, Ye LJ, Wang XH, Yu H. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China. World J Pediatr 2019;15:595-600. [PMID: 31487005 DOI: 10.1007/s12519-019-00303-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
247 Wu Y, Zeng Y, Wu W, Lin J, Ou Q. Polymorphisms of CYP27B1 are associated with IFN efficacy in HBeAg-positive patients. J Clin Lab Anal 2018;32:e22367. [PMID: 29457277 DOI: 10.1002/jcla.22367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
248 Schinazi RF, Ehteshami M, Bassit L, Asselah T. Towards HBV curative therapies. Liver Int 2018;38 Suppl 1:102-14. [PMID: 29427479 DOI: 10.1111/liv.13656] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 19.0] [Reference Citation Analysis]
249 Heo NY. Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign? Clin Mol Hepatol 2017;23:125-7. [PMID: 28669139 DOI: 10.3350/cmh.2017.0106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
250 Chen CC, Wang PC, Chang HW, Chen CF. Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation. J Viral Hepat. 2012;19:161-172. [PMID: 22329370 DOI: 10.1111/j.1365-2893.2011.01469.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
251 Sun J, Ding H, Chen G, Wang G, Wei L, Zhang J, Xie Q, Wan M, Tang H, Chen S, Gao Z, Wang Y, Zhang D, Huang W, Sheng J, Ning Q, Yang D, Lu J, Pan C, Yang Y, Wang J, Sun C, Wang Q, Hou J. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China. BMC Gastroenterol 2019;19:65. [PMID: 31046700 DOI: 10.1186/s12876-019-0981-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
252 Jun DW, Ahn SB, Kim TY, Sohn JH, Kim SG, Lee SW, Kim BH, Kim DJ, Kim JK, Kim HS, Hwang SG, Choi WC, Tak WY, Lee HJ, Yoon KT, Yun BC, Lee SW, Baik SK, Park SH, Park JW, Park SJ, Lee JS. Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study). Chin Med J (Engl) 2018;131:1645-51. [PMID: 29998882 DOI: 10.4103/0366-6999.235880] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
253 Hou FQ, Song LW, Yuan Q, Fang LL, Ge SX, Zhang J, Sheng JF, Xie DY, Shang J, Wu SH, Sun YT, Wei SF, Wang MR, Wan MB, Jia JD, Luo GH, Tang H, Li SC, Niu JQ, Zhou WD, Sun L, Xia NS, Wang GQ. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics 2015;5:218-26. [PMID: 25553110 DOI: 10.7150/thno.10636] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
254 Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 125-140 [PMID: 17206760 DOI: 10.3748/wjg.v13.i1.125] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
255 Mahdavi M, Amirrasouli H, Alavian SM, Behnava B, Kazerouni F, Keshvari M, Namaki S, Gholami Fesharaki M, Rahimipour H, Mohammadzade J. Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study. Hepat Mon. 2013;13:e11903. [PMID: 24348645 DOI: 10.5812/hepatmon.11903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
256 Zhou J, Wu X, Wei W, You H, Jia J, Kong Y. A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B. Int J Environ Res Public Health 2016;13:E730. [PMID: 27455288 DOI: 10.3390/ijerph13070730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
257 Toy M, Hutton DW, So SK. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One 2015;10:e0139876. [PMID: 26536626 DOI: 10.1371/journal.pone.0139876] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
258 Chang BW, Kaung A, Robbins L, Tran TT. Hepatitis B: Working Towards a Cure. Curr Gastroenterol Rep 2015;17:35. [PMID: 26275560 DOI: 10.1007/s11894-015-0460-2] [Reference Citation Analysis]
259 Hao Z, Biqing Z, Ling Y, Wenting Z. The Effectiveness of Antiviral Treatments for Patients with HBeAg-Positive Chronic Hepatitis B: A Bayesian Network Analysis. Can J Gastroenterol Hepatol 2018;2018:3576265. [PMID: 30276197 DOI: 10.1155/2018/3576265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
260 Mohd-Ismail NK, Lim Z, Gunaratne J, Tan YJ. Mapping the Interactions of HBV cccDNA with Host Factors. Int J Mol Sci. 2019;20. [PMID: 31480501 DOI: 10.3390/ijms20174276] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
261 Yano Y, Seo Y, Hayashi H, Hatazawa Y, Hirano H, Minami A, Kawano Y, Saito M, Ninomiya T, Sugano M, Yamada H, Kitajima N, Yoon S, Hayashi Y. Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective? Biomed Rep 2017;7:257-62. [PMID: 28819561 DOI: 10.3892/br.2017.944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
262 Tantai N, Chaikledkaew U, Tanwandee T, Werayingyong P, Teerawattananon Y. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. BMC Health Serv Res 2014;14:170. [PMID: 24731689 DOI: 10.1186/1472-6963-14-170] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
263 Lv GC, Yao JM, Yang YD, Zheng L, Sheng JF, Chen Y, Li LJ. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(22): 3481-3486 [PMID: 23801842 DOI: 10.3748/wjg.v19.i22.3481] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
264 Xu B, Zhou NM, Cao WT, Li XJ. Evaluation of elastography combined with serological indexes for hepatic fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2018; 24(37): 4272-4280 [PMID: 30310260 DOI: 10.3748/wjg.v24.i37.4272] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
265 Yu Y, Hou J, Omata M, Wang Y, Li L. Loss of HBsAg and antiviral treatment: from basics to clinical significance. Hepatol Int 2014;8:39-54. [PMID: 26202405 DOI: 10.1007/s12072-013-9495-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
266 Yilmaz A, Akcam M, Gelen T, Artan R. Lamivudine and high-dose interferon alpha 2a combination treatment in naïve HBeAg-positive immunoactive chronic hepatitis B in children: an East Mediterranean center’s experience. Eur J Pediatr. 2007;166:195-199. [PMID: 16944240 DOI: 10.1007/s00431-006-0220-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
267 Kim SR, Yang J, Kudo M, Hino O. Recent advances in the management of chronic hepatitis B. Hepat Mon 2011;11:601-11. [PMID: 22140383 DOI: 10.5812/kowsar.1735143x.657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
268 Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 2012;86:7256-67. [PMID: 22532692 DOI: 10.1128/JVI.07222-11] [Cited by in Crossref: 122] [Cited by in F6Publishing: 83] [Article Influence: 13.6] [Reference Citation Analysis]
269 Marzio DHD, Hann HW. Then and now: The progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014; 20(2): 401-413 [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
270 Drazilova S, Janicko M, Kristian P, Schreter I, Kucinsky B, Kozlej M, Hockickova I, Jarcuska P. Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia. Gastroenterol Res Pract 2016;2016:8682494. [PMID: 26858755 DOI: 10.1155/2016/8682494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
271 Tian C, Chen Y, Liu Y, Wang S, Li Y, Wang G, Xia J, Zhao XA, Huang R, Lu S, Wu C. Use of ELISpot assay to study HBs-specific B cell responses in vaccinated and HBV infected humans. Emerg Microbes Infect 2018;7:16. [PMID: 29449582 DOI: 10.1038/s41426-018-0034-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
272 Chen J, Wu M, Wang F, Zhang W, Wang W, Zhang X, Zhang J, Liu Y, Liu Y, Feng Y, Zheng Y, Hu Y, Yuan Z. Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy. Sci Rep 2015;5:16459. [PMID: 26585041 DOI: 10.1038/srep16459] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
273 熊英. 阿德福韦酯联合拉米夫定抗病毒治疗慢性乙型肝炎32例. 世界华人消化杂志 2010; 18(18): 1932-1935 [DOI: 10.11569/wcjd.v18.i18.1932] [Reference Citation Analysis]
274 Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (Lond) 2019;14:93-126. [PMID: 30451076 DOI: 10.2217/nnm-2018-0120] [Cited by in Crossref: 143] [Cited by in F6Publishing: 100] [Article Influence: 47.7] [Reference Citation Analysis]
275 Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuismink ZMA, Santoro R, Jaroszewicz J, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen HLA; GIANT-B Global Consortium. Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. Clin Infect Dis 2019;69:1969-79. [PMID: 30715261 DOI: 10.1093/cid/ciz084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
276 Kwon JH, Kim YS, Kim SG, Jang JW, Kim TH, Jung YK, Kwon OS. The Efficacy and Safety of Peginterferon-α-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting. Gut Liver. 2013;7:197-205. [PMID: 23560156 DOI: 10.5009/gnl.2013.7.2.197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
277 Li MH, Zhang L, Qu XJ, Lu Y, Shen G, Wu SL, Chang M, Liu RY, Hu LP, Li ZZ, Hua WH, Song SJ, Xie Y. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment. Chin Med J (Engl) 2017;130:559-65. [PMID: 28229987 DOI: 10.4103/0366-6999.200554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
278 Zoulim F. Emerging drugs for hepatitis B. Expert Opin Emerg Drugs 2007;12:199-217. [PMID: 17604497 DOI: 10.1517/14728214.12.2.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
279 Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 2009;3:5-15. [PMID: 19763714 DOI: 10.1007/s12072-009-9149-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
280 Tillmann HL. The treatment of chronic hepatitis B: Focus on adefovir-like antivirals. Ther Clin Risk Manag 2008;4:797-802. [PMID: 19209262 DOI: 10.2147/tcrm.s1965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
281 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
282 Rajbhandari R, Chung RT. Treatment of Hepatitis B: A Concise Review. Clin Transl Gastroenterol 2016;7:e190. [PMID: 27628420 DOI: 10.1038/ctg.2016.46] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
283 Wang X, Chi X, Wu R, Xu H, Gao X, Yu L, Liu L, Zhang M, Tan Y, Niu J, Jin Q. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. Virol J 2021;18:4. [PMID: 33407619 DOI: 10.1186/s12985-020-01471-2] [Reference Citation Analysis]
284 Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother. 2015;59:4121-4128. [PMID: 25941216 DOI: 10.1128/AAC.00249-15] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 6.2] [Reference Citation Analysis]
285 Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015; 7(11): 1541-1552 [PMID: 26085913 DOI: 10.4254/wjh.v7.i11.1541] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
286 Li X, Liu X, Tian L, Chen Y. Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections. Clin Rev Allergy Immunol. 2016;50:41-54. [PMID: 25480494 DOI: 10.1007/s12016-014-8465-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
287 Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association., Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017;5:297-318. [PMID: 29226097 DOI: 10.14218/JCTH.2016.00019] [Cited by in Crossref: 109] [Cited by in F6Publishing: 59] [Article Influence: 27.3] [Reference Citation Analysis]
288 Shen X, Fu B, Liu Y, Guo C, Ye Y, Sun R, Li J, Tian Z, Wei H. NKp30+ NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B. Sci Rep 2016;6:38778. [PMID: 27941937 DOI: 10.1038/srep38778] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
289 Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33. [PMID: 19669245 DOI: 10.1007/s12072-009-9140-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 6.6] [Reference Citation Analysis]
290 Yu S, Zhou Q, Zhao XM, Yuan M, Wang CT, Cheng XG, Zhang ZH, Li X. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study. Saudi J Gastroenterol. 2014;20:350-355. [PMID: 25434315 DOI: 10.4103/1319-3767.145320] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
291 Wang YC, Yang SS, Su CW, Wang YJ, Lee KC, Huo TI, Lin HC, Huang YH. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Sci Rep. 2016;6:29605. [PMID: 27405043 DOI: 10.1038/srep29605] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
292 Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. PLoS One. 2015;10:e0122259. [PMID: 25835020 DOI: 10.1371/journal.pone.0122259] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
293 Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Treeprasertsuk S, Tanwandee T, Charatcharoenwitthaya P, Thongsawat S, Leerapun A, Piratvisuth T, Boonsirichan R, Bunchorntavakul C, Pattanasirigool C, Pornthisarn B, Tuntipanichteerakul S, Sripariwuth E, Jeamsripong W, Sanpajit T, Poovorawan Y, Komolmit P. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study. Asian Pac J Cancer Prev 2019;20:1257-64. [PMID: 31030503 DOI: 10.31557/APJCP.2019.20.4.1257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
294 Furutani Y, Toguchi M, Shiozaki-Sato Y, Qin XY, Ebisui E, Higuchi S, Sudoh M, Suzuki H, Takahashi N, Watashi K, Wakita T, Kakeya H, Kojima S. An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes. PLoS One 2019;14:e0216139. [PMID: 31188831 DOI: 10.1371/journal.pone.0216139] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
295 Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 2011;86:1009-26. [PMID: 21964179 DOI: 10.4065/mcp.2011.0309] [Cited by in Crossref: 137] [Cited by in F6Publishing: 106] [Article Influence: 13.7] [Reference Citation Analysis]
296 Piratvisuth T, Marcellin P, Popescu M, Kapprell H, Rothe V, Lu Z. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2013;7:429-36. [DOI: 10.1007/s12072-011-9280-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 7.2] [Reference Citation Analysis]
297 Zhang S, Guo JT, Wu JZ, Yang G. Identification and characterization of multiple TRIM proteins that inhibit hepatitis B virus transcription. PLoS One 2013;8:e70001. [PMID: 23936368 DOI: 10.1371/journal.pone.0070001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
298 Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, Chuang WL, Tabak F, Mehta R, Petersen J, Guyer W, Jump B, Chan A, Subramanian M, Crans G, Fung S, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HLY. Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. Dig Dis Sci 2018;63:3487-97. [PMID: 30136045 DOI: 10.1007/s10620-018-5251-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
299 Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699-705. [PMID: 17127704 DOI: 10.1136/gut.2005.089722] [Cited by in Crossref: 189] [Cited by in F6Publishing: 176] [Article Influence: 12.6] [Reference Citation Analysis]
300 Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV therapy. Viruses 2009;1:484-509. [PMID: 21994557 DOI: 10.3390/v1030484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
301 Lu H, Geng da Y, Shen F, Zhang JY, Lu B, Ma LX. Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study. Virol J 2011;8:444. [PMID: 21936898 DOI: 10.1186/1743-422X-8-444] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
302 Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis. 2011;11:165. [PMID: 21651820 DOI: 10.1186/1471-2334-11-1651471-2334-11-165] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
303 Ataei B, Khodadoostan M, Pouria B, Adibi P. Tenofovir in treatment of Iranian patients with chronic hepatitis B virus infection: An open-label case series. J Res Pharm Pract 2016;5:166-70. [PMID: 27512706 DOI: 10.4103/2279-042X.185714] [Reference Citation Analysis]
304 Zhou P, Yang F, Wang J, Mao R, Qi X, Huang Y, Zhang J. Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients. Medicine (Baltimore) 2015;94:e730. [PMID: 25929904 DOI: 10.1097/MD.0000000000000730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
305 Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersöz G, Ozenirler S, Kalayci C, Poturoglu S, Cakaloglu Y, Okten A. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother 2007;51:3020-2. [PMID: 17517832 DOI: 10.1128/AAC.00088-07] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
306 Takamatsu Y, Tanaka Y, Kohgo S, Murakami S, Singh K, Das D, Venzon DJ, Amano M, Higashi-Kuwata N, Aoki M. 4’-modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus. Hepatology. 2015;62:1024-1036. [PMID: 26122273 DOI: 10.1002/hep.27962] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
307 Lv LL, Yang YX, Shi TD. Effect of haptoglobin on the treatment of chronic hepatitis B with interferon. Exp Ther Med 2019;18:1417-25. [PMID: 31316628 DOI: 10.3892/etm.2019.7661] [Reference Citation Analysis]
308 De Clercq E, Férir G, Kaptein S, Neyts J. Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses 2010;2:1279-305. [PMID: 21994680 DOI: 10.3390/v2061279] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
309 Kosinska AD, Zhang E, Lu M, Roggendorf M. Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat 2010;2010:817580. [PMID: 21188201 DOI: 10.1155/2010/817580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
310 Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6:975-90. [PMID: 18049472 DOI: 10.1038/nrd2422] [Cited by in Crossref: 746] [Cited by in F6Publishing: 722] [Article Influence: 53.3] [Reference Citation Analysis]
311 Lal BB, Sood V, Khanna R, Rawat D, Verma S, Alam S. Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children. Indian J Gastroenterol 2018;37:326-34. [PMID: 30168073 DOI: 10.1007/s12664-018-0878-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
312 Lv GC, Ma WJ, Ying LJ, Jin X, Zheng L, Yang YD. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. World J Gastroenterol 2010; 16(32): 4095-4099 [PMID: 20731026 DOI: 10.3748/wjg.v16.i32.4095] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
313 Wei W, Wu Q, Zhou J, Kong Y, You H. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis. Int J Environ Res Public Health 2015;12:10039-55. [PMID: 26308024 DOI: 10.3390/ijerph120810039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
314 Block TM, Guo H, Guo JT. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis. 2007;11:685-706, vii. [PMID: 17981225 DOI: 10.1016/j.cld.2007.08.002] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 7.6] [Reference Citation Analysis]
315 Chon YE, Kim DJ, Kim SG, Kim IH, Bae SH, Hwang SG, Heo J, Jang JW, Lee BS, Kim HJ, Jun DW, Kim KM, Chung WJ, Choi MS, Jang JY, Yim HJ, Tak WY, Yoon KT, Park JY, Han KH, Suk KT, Lee HW, Jang BK, Ahn SH. An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study. Medicine (Baltimore) 2016;95:e3026. [PMID: 27057828 DOI: 10.1097/MD.0000000000003026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
316 Itokawa N, Atsukawa M, Tsubota A, Shimada N, Toyoda H, Takaguchi K, Hiraoka A, Senoh T, Koeda M, Yoshida Y, Okubo T, Arai T, Hayama K, Nakagawa-Iwashita A, Kondo C, Iwakiri K. Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B. Intern Med 2021;60:507-16. [PMID: 33583931 DOI: 10.2169/internalmedicine.5432-20] [Reference Citation Analysis]
317 Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS. Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. Viruses 2017;9:E96. [PMID: 28468285 DOI: 10.3390/v9050096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
318 Lin CL, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5:a021436. [PMID: 25934462 DOI: 10.1101/cshperspect.a021436] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 18.3] [Reference Citation Analysis]
319 Lee IC, Huang YH, Su CW, Wang YJ, Huo TI, Lee KC, Lin HC. CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study. PLoS One. 2013;8:e76798. [PMID: 24124595 DOI: 10.1371/journal.pone.0076798] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
320 Roggendorf M, Kosinska AD, Liu J, Lu M. The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection. Cold Spring Harb Perspect Med. 2015;5. [PMID: 26511761 DOI: 10.1101/cshperspect.a021451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
321 Nitschmann S. [Treatment options in chronic hepatitis B]. Internist (Berl) 2006;47:308-9; discussion 309-10. [PMID: 16485097 DOI: 10.1007/s00108-005-1573-8] [Reference Citation Analysis]
322 Sajid M, Ullah H, Yan K, He M, Feng J, Shereen MA, Hao R, Li Q, Guo D, Chen Y, Zhou L. The Functional and Antiviral Activity of Interferon Alpha-Inducible IFI6 Against Hepatitis B Virus Replication and Gene Expression. Front Immunol 2021;12:634937. [PMID: 33868257 DOI: 10.3389/fimmu.2021.634937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
323 Smith MA, Chiang CC, Zerrouki K, Rahman S, White WI, Streicher K, Rees WA, Schiffenbauer A, Rider LG, Miller FW, Manna Z, Hasni S, Kaplan MJ, Siegel R, Sinibaldi D, Sanjuan MA, Casey KA. Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. Sci Rep 2020;10:4462. [PMID: 32157125 DOI: 10.1038/s41598-020-60563-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]